Incstar launches hepatitis test line
This article was originally published in Clinica
Incstar has launched a line of seven hepatitis A and B tests following FDA approval of the final two tests in the microtitre-plate panel. There are 300,000 cases and 5,000 deaths from hepatitis B every year in the US. CDC estimates that there are 1.2 million carriers and the American Liver Foundation says total cost of treating the disease is more than $209 million. Hepatitis A is usually self-limiting. Incstar believes the US market for hepatitis A and B testing is worth $160 million and growing at 5% a year.